Warning letter
K.C. Pharmaceuticals Inc.: warning letter of Aug 3, 2023
FDA warning letter 654986 · Division of Pharmaceutical Quality Operations IV
Key facts
| Reference number | 654986 |
|---|---|
| Company | K.C. Pharmaceuticals Inc. |
| Subject | CGMP/Finished Pharmaceuticals/Adulterated |
| Issue date | Aug 3, 2023 |
| Posted date | Aug 29, 2023 |
| Issuing office | Division of Pharmaceutical Quality Operations IV |
| Product type | Drugs |
| CFR sections cited | 211.67(b), 211.34, 211.42(c)(10), 211.113(b) |
| Inspection city | Pomona |
| Inspection ZIP | 91768 |
| Inspection start date | Jan 18, 2023 |
| Letter on fda.gov | fda.gov |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: